In the case of RA, different strategies have been tested in animal models with complement blockers such as soluble CR1 (which suppresses complement activation at the C3 level) [175], or recombinant C3a and C5a receptor antagonists [176,177], and CD59 (which inhibits the formation of MAC) [178]. Here, C3 is linked to rheumatoid arthritis.